[Issues related to basic research on uterine and ovarian tumor pathology].
Lin
Zhen-hua
ZH
Department of Pathology, Johns Hopkins University Medical Institutions, Baltimore, MD 21231, USA.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001897:Boronic Acids / Q000627:therapeutic use; D000069286:Bortezomib; D005260:Female; D052162:Human papillomavirus 16 / Q000302:isolation & purification; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology*; D030361:Papillomavirus Infections; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000378:metabolism; D016283:Proto-Oncogene Proteins p21(ras); D011719:Pyrazines / Q000627:therapeutic use; D000068878:Trastuzumab; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism*; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000821:virology; D018631:ras Proteins / Q000378:metabolism; D002578:Uterine Cervical Dysplasia / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001897:Boronic Acids; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D011719:Pyrazines; D016159:Tumor Suppressor Protein p53; D000069286:Bortezomib; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins; D000068878:Trastuzumab